Amgen News - LARVOL Sigma

«1 2...42 43 44 45 464748 49 50 51 52...858 859 »

|||||||||| Bone Disease and Osteoporosis Associated with Pompe Disease (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1077;

|||||||||| raloxifene hydrochloride / Generic mfg.
Trends in the Use of Raloxifene for Osteoporosis, 1999-2022 (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1046;

|||||||||| Prolia (denosumab) / Amgen
Denosumab Discontinuation and the Rebound Phenomenon: A Case Report (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1045;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among Postmenopausal Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies in the US (2019 (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1040;

|||||||||| Exploring Risk Factors and Time-To-Onset Antiresorptive Drug-induced Osteonecrosis of the Jaw (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1039;

|||||||||| The use of 3D-DXA cortical and trabecular parameters in combination with areal bone mineral density better captures responders to osteoporosis drug treatments (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1038;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Is it possible to identify patients who will not respond to romosozumab? (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1036;

|||||||||| Prolia (denosumab) / Amgen
Assessing for Risk Factors for Medication-Related Osteonecrosis of the Jaw in Men and Women Prescribed Bisphosphonates or Denosumab for Fracture Prevention (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1034;

|||||||||| Prolia (denosumab) / Amgen
Use of bisphosphonates to prevent bone loss with denosumab discontinuation: observations from clinical practice (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1033;

|||||||||| Prolia (denosumab) / Amgen
Bone Mineral Density Changes in Postmenopausal Women Switching from 30 mg Denosumab to Intravenous Zoledronic Acid: A Prospective Observational Study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1030;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Efficacy and Safety of Romosozumab Treatment in Male and Female Patients with Osteoporosis. A Retrospective Cohort Study at a Single Clinical Center (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1029;

|||||||||| Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1028;

|||||||||| Prior Treatment With Sequences of RANKL Inhibitor and Bisphosphonates Modifies the Tissue-Level Response of Vertebral Cancellous and Cortical Bone to Sclerostin Antibody in Ovariectomized Rats (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1026;

|||||||||| Prolia (denosumab) / Amgen
Identification and Classification of Periprosthetic Fractures with Atypical Features among Bisphosphonate (BP) and Denosumab Exposed Patients with Prior Total Hip Arthroplasties: Findings from a Veterans Health Administration Cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1013;

|||||||||| Association of Bone Mineral Density (BMD) and Hip Fracture Risk among Asian and non-Hispanic White Women in a Western US Healthcare Population (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1008;

|||||||||| Association of Serum Pentosidine and Atypical Femur Fractures: a Case-Control Study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_891;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Effects of Anabolic Treatments with Teriparatide and Romosozumab on Bone in +/G610C Mouse Model of Adult Osteogenesis Imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_879;

|||||||||| ALP as a surrogate marker for estimating bone turnover in hemodialysis patients (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_748;

|||||||||| Prolia (denosumab) / Amgen
Treatment of 1,25-D mediated Hypercalcemia and Extraosseous Giant Cell Tumor in Paget Disease of Bone with Denosumab (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_739;

|||||||||| Cohort profile : Health Outcome of Hyperparathyroidism Evolvement (HOPE) cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_733;

|||||||||| Prolia (denosumab) / Amgen
Oscillating Episodes of Hypocalcemia and Hypercalcemia in a Prostate Cancer Patient Undergoing Intermittent Denosumab Therapy (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_731;

|||||||||| Prolia (denosumab) / Amgen
Denosumab for the Treatment of Aneurysmal Bone Cyst in a 10-Year-Old Boy (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_713;

|||||||||| Prolia (denosumab) / Amgen
Denosumab Discontinuation - Clinical Experience (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_711;

|||||||||| Cell cycle inhibition reduces cell growth and mineralization in MAP2K1+ melorheostosis: Opening a pathway to treatment for classical melorheostosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_688;

|||||||||| Comparison of the role of bone turnover markers P1NP, CTX and NTX and safety in patients on antiresorptive therapy undergoing dental extractions. (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_664;

|||||||||| Bioactive Monomer CMET Promotes Odontoblast Differentiation in Type I Collagen 3D Culture System (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_658;

|||||||||| Efficacy of Anti-Osteoporosis Therapy in Women Under and Over Age 75: an Analysis of the FNIH-ASBMR-SABRE Database (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_647;

|||||||||| Factors associated with BMD response to 1-year treatment with anti-osteoporotic medications in osteoporosis management (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_646;

|||||||||| How to Manage Paget's Disease of Bone (PDB) in a Patient with Chronic Kidney Disease (CKD)? (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_600;

|||||||||| Disability, functional limitation, and use of anti-fracture drug therapies in a cohort of 3651 U.S. adults with osteogenesis imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_564;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Expected Fracture Outcomes and Associated Costs of Romosozumab Preceding or Following Alendronate in Postmenopausal Women at Very High Fracture Risk in the United States (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_552;

|||||||||| Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_551;

|||||||||| Effects of different antiresorptive treatment on medication-related osteonecrosis of the jaw in patients undergoing dental procedures: A systematic review and network meta-analysis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_548;

|||||||||| Prior Treatment With Sequences of RANKL Inhibitor and Bisphosphonates Modifies the Tissue-Level Response of Vertebral Cancellous and Cortical Bone to Sclerostin Antibody in Ovariectomized Rats (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_547;

|||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_546;

|||||||||| Association of Bone Mineral Density (BMD) and Hip Fracture Risk among Asian and non-Hispanic White Women in a Western US Healthcare Population (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_542;

|||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice (Meeting Room 714/716 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_405;

|||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
A Comparative Study of the Effects of 12-Month Romosozumab Treatment versus Sequential Treatment with 6 Months of Romosozumab Followed by Denosumab in Korean population: A Multi-center Retrospective Study (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_355;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Rates of Concurrent BMD Responses at the Lumbar Spine and Total Hip in Patients Receiving Romosozumab or Teriparatide following Bisphosphonate Therapy: A Post Hoc Analysis of the Randomized Phase 3 STRUCTURE Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_354;

|||||||||| Prolia (denosumab) / Amgen
Denosumab Increases Bone Mass in Postmenopausal Women and Older Men Undergoing Bariatric Surgery: A Randomized Controlled Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_332;

|||||||||| Prolia (denosumab) / Amgen
Efficacy and Safety of Zoledronate, Denosumab and Teriparatide In Postmenopausal Women with Type 2 Diabetes Mellitus at High-Risk of Fragility Fractures: Results from a Randomized Pilot Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_331;

|||||||||| Proteomic Analysis of Bone from Ovariectomized Cynomolgus Monkeys Treated with Antiresorptive Agents Shows Differential Regulation of Cholesterol Metabolism (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_288;

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Is Effective in Patients with Early-Onset Osteoporosis due to Variants in WNT1 or LRP5/6 (Meeting Room 801 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_279;

|||||||||| Prolia (denosumab) / Amgen
Denosumab Withdrawal (Meeting Room 713A South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_215;

||||||||||  Nplate (romiplostim) / Amgen
Enrollment closed, Trial completion date:  Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia (clinicaltrials.gov) -  Aug 4, 2024
P=N/A, N=36, Active, not recruiting,  Sponsor: Kyowa Kirin Co., Ltd.
Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2026

||||||||||  Stivarga (regorafenib) / Bayer, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Trial completion date, Trial primary completion date:  Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients with Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov) -  Aug 4, 2024
P1/2, N=63, Recruiting,  Sponsor: City of Hope Medical Center
Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2026 Trial completion date: Nov 2024 --> Oct 2025 | Trial primary completion date: Nov 2024 --> Oct 2025

||||||||||  tezampanel (LY-293558) / Proniras Corp
New P1 trial:  Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder (clinicaltrials.gov) -  Aug 4, 2024
P1, N=40, Not yet recruiting,  Sponsor: Proniras Corporation

||||||||||  hydroxyurea / Generic mfg.
Trial primary completion date:  ACHiEvE-SCD: Hydroxyurea and EPO in Sickle Cell Disease (clinicaltrials.gov) -  Aug 4, 2024
P1/2, N=15, Recruiting,  Sponsor: Julia Xu
Trial completion date: Nov 2024 --> Oct 2025 | Trial primary completion date: Nov 2024 --> Oct 2025 Trial primary completion date: Nov 2024 --> May 2025

|||||||||| Imdelltra (tarlatamab-dlle) / Amgen
DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (Exhibit Hall) - Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2696;
P3
Other secondary endpoints include investigator-assessed PFS, investigator and BICR-assessed objective response rate, disease control rate, duration of response, time to progression (all per RECIST 1.1), incidence of treatment-emergent and treatment-related adverse events, serum concentrations of tarlatamab, and incidence of anti-tarlatamab antibody formation. This trial is actively recruiting patients.

|||||||||| Epogen (epoetin alfa) / Amgen
Journal: Evaluation of serum ferritin level and hepatitis b and hepatitis c viral infection in chronic hemodialysis patients. (Pubmed Central) - Aug 4, 2024
The study aimed to assess serum ferritin levels and their connection to Epoetin alfa resistance, along with exploring the link between hepatitis C virus, iron overload, and the prevalence of hepatitis C and B infections in chronic HD patients...Excessive blood transfusions can lead to iron overload and inhibit erythropoiesis. Maintaining HB at 110-120 g/l improves quality of life and reduces anemia-related risks.



	Diseases Companies Products Productz Mechanisms of Action Sites